Akttyva Therapeutics

Executive Summary

Akttyva Therapeutics is a private AI-driven drug discovery company founded in 2021 by pharmaceutical industry veterans. Headquartered in San Francisco, the company leverages its proprietary AIDE v.2 platform, which integrates artificial intelligence with human expertise in biology and computational science. Akttyva's pipeline is focused on developing targeted therapies for conditions involving vascular leakage pathologies, a critical area of unmet medical need. By combining advanced machine learning with deep biological insight, the company aims to identify and optimize novel therapeutic candidates more efficiently than traditional approaches. As a private entity with limited public data, Akttyva represents an early-stage investment opportunity in the rapidly evolving AI-biotech space. The company's success hinges on platform validation, securing partnerships, and advancing lead programs toward preclinical and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026Publication of AIDE v.2 Platform Validation Data40% success
• Q4 2026Announcement of pharma partnership or co-development deal30% success
• Q1 2027Nomination of lead candidate for vascular leakage program50% success